A cooperative model may at time better serve the relationship between patient and clinician.

Sacituzumab tirumotecan showed “promising efficacy” regardless of PD-L1 status, said study presenter Yongmei Yin, MD, PhD.

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with ...

Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely ...